Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2022 | Novel agents to treat psychosis in Alzheimer’s disease

Byron Creese • 1 Mar 2022
ARUK 2022
Alzheimer’s Disease Dementia Pimavanserin

Byron Creese, PhD, University of Exeter Medical School, Exeter, UK, discusses treatments for psychosis in Alzheimer’s disease that are currently being investigated. There is a great unmet need for novel treatments in this area. Pimavanserin shows promise but there is debate as to its efficacy. This interview took place at the Alzheimer’s Research UK Conference 2022 in Brighton, UK.

More from Byron Creese

1:05
Using neuropsychiatric symptoms as clinical markers for dementia diagnosis
Byron Creese • 17 Jul 2023
2:00
Molecular processes driving psychosis in Alzheimer’s disease
Byron Creese • 17 Jul 2023
2:50
Behavioral changes and dementia risk
Byron Creese • 17 Jul 2023
1:32
Pharmacological vs. non-pharmacological treatment options for psychosis in AD
Byron Creese • 1 Mar 2022

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:31
Barriers to dementia treatment: awareness, accessibility, and affordability
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals